Chemotherapeutic trials with different regimens containing XXXX in @entity5117 cases--a preliminary report.

@entity5117 @entity1 @entity3761 @entity1215
Different regimens containing @entity1215 have been tried in treating @entity5117 @entity1 . In our study we have studied three regimens. Regimen I consists of treating @entity1 with @entity1215 600 mg once a month for six months combined with @entity3761 100mg daily and treatment is stopped at six months. Regimen II is same as regimen I except that instead of stopping treatment at the end of six months the treatment was continued with @entity3761 100 mg daily for another six months and treatment was stopped at one year. Regimen III is the same as recommended by I.A.L. in which treatment is started with @entity1215 600 mg daily for seven days in the first month to be followed by @entity1215 600 mg once a month for five more months. This is combined with @entity3761 100mg daily for one year. Treatment in this group is also stopped at one year. Eighty one @entity1 in Regimen I, thirty five @entity1 in Regimen II and sixty three @entity1 in Regimen III completed the six month treatment. It was found that the inactivation index in all the three regimens was nearly the same.
